Current Approaches for New TB Drugs
Shilpika Pandey, Isha Soni, Neha Topno, Arunava Dasgupta and Sidharth ChopraAffiliation:
Division of Microbiology, CSIR-Central Drug Research Institute, B.S. 10/1, Sector 10, Janakipuram Extension, Sitapur Road, Lucknow - 226031, India.
AbstractTuberculosis is essentially a curable disease but inspite of a WHO approved DOTS therapy, it still continues to ravage mankind. This situation is exacerbated by long course of chemotherapy, increasing drug resistance and co-emergence with HIV. The TB drug pipeline remained stagnant for a long time with no new drug approved till FDA approval for Bedaquiline. This situation has now improved with a number of agents in pre-clinical and clinical development against M. tuberculosis. In this review, we are focusing on some of the newer drugs in discovery and preclinical development against M. tuberculosis.
Clinical strains, drugs, MIC, Mycobacterium, pre-clinical development, tuberculosis.
Purchase Online Order Reprints Order Eprints Rights and Permissions